Aptar Digital Health announced that the FDA has granted 510(k) clearance for HeroTracker Sense as a Class II medical device.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATR:
- AptarGroup price target lowered to $167 from $175 at BofA
- Nasus Pharma announces expanded agreement to support NS002
- AptarGroup’s Strategic Shift to Pharma Drives Buy Rating Amid Profitability Gains
- AptarGroup price target lowered to $152 from $153 at Wells Fargo
- AptarGroup: Balancing Long-Term Potential with Short-Term Challenges – Hold Rating